arrow
C

C. Bulaï Livideanu

larrey hospital
H指数:28
被引数:2,746

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study

儿童期发病的非肥大细胞增多症肥大细胞活化障碍患者的特征与结局:CEREMAST研究

2026-05-180
OAAI
Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

整合临床试验与分子谱分析揭示慢性手部湿疹的免疫驱动因素

2026-02-180
OAAI
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study

阿伐普利尼布在晚期系统性肥大细胞增多症中的有效性和安全性:PATHFINDER研究的4年随访

2026-01-300
OAAI
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation

KIT D816V在过敏性休克或系统性肥大细胞活化中的流行率

2025-10-250
OAAI
Efficacy of anifrolumab in lupus erythematous panniculitis: A retrospective study of 11 patients

安普利单抗在红斑狼疮性脂膜炎中的疗效:一项11例患者的回顾性研究

2025-07-190
PRE
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study

患者报告结局和医疗提供者对系统性肥大细胞增多症的认知:PRISM研究的结果

2025-06-270
PREAI
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes

所有肥大细胞增多症亚型中遗传性 α-胰蛋白酶血症患病率升高的病理生理意义

2024-01-019
OA
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders

克隆性肥大细胞疾病患者的有效Anti-SARS-CoV-2免疫反应

2022-05-012
OAAI
Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr)

阿达木单抗、依那西普和乌司他单抗治疗12岁以下儿童严重银屑病的有效性和安全性: 法国-意大利每日实践队列 (BiPe Jr)

2022-04-105
OA